Could Immunomedics, Inc. (IMMU) Change Direction After This Double Top Chart Pattern

March 14, 2018 - By Peter Erickson

Investors sentiment increased to 1.65 in 2017 Q3. Its up 0.24, from 1.41 in 2017Q2. It improved, as 16 investors sold Immunomedics, Inc. shares while 36 reduced holdings. 38 funds opened positions while 48 raised stakes. 111.69 million shares or 33.14% more from 83.89 million shares in 2017Q2 were reported.
Geode Cap Mngmt Ltd Liability Corp invested in 911,926 shares or 0% of the stock. Federated Investors Pa holds 0% or 100,997 shares. Credit Suisse Ag accumulated 129,313 shares. State Bank Of Ny Mellon Corporation owns 681,419 shares. Nationwide Fund Advisors holds 0% or 56,912 shares. Pnc stated it has 1,721 shares. Great West Life Assurance Can invested in 21,882 shares. Advisory Ntwk Lc has invested 0% in Immunomedics, Inc. (NASDAQ:IMMU). Natl Bank Of Montreal Can holds 0% or 14,650 shares in its portfolio. Atika Lc invested 0.54% in Immunomedics, Inc. (NASDAQ:IMMU). Moreover, Panagora Asset Mgmt has 0.04% invested in Immunomedics, Inc. (NASDAQ:IMMU). Voya Mgmt Ltd Co owns 50,433 shares. Commonwealth Equity Inc reported 18,000 shares. Axiom Investors Lc De has 200,587 shares. Tci Wealth Advisors Incorporated invested in 6,000 shares or 0.04% of the stock.

Since February 28, 2018, it had 0 insider buys, and 1 insider sale for $2.05 million activity.

The chart of Immunomedics, Inc. (IMMU) shows a double top with $16.72 target or 4.00 % above today’s $16.08 share price. The 9 months chart pattern indicates low risk for the $2.67B company. It was reported on Mar, 14 by If the $16.72 price target is reached, the company will be worth $106.64 million more. Double tops are rare but powerful chart patterns.

The stock decreased 5.08% or $0.86 during the last trading session, reaching $16.08. About 1.56 million shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 76.26% since March 14, 2017 and is uptrending. It has outperformed by 59.56% the S&P500.

Analysts await Immunomedics, Inc. (NASDAQ:IMMU) to report earnings on May, 9. They expect $-0.13 EPS, up 40.91 % or $0.09 from last year’s $-0.22 per share. After $-0.19 actual EPS reported by Immunomedics, Inc. for the previous quarter, Wall Street now forecasts -31.58 % EPS growth.

Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage

Among 3 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Immunomedics had 15 analyst reports since July 29, 2015 according to SRatingsIntel. Jefferies maintained Immunomedics, Inc. (NASDAQ:IMMU) rating on Friday, June 9. Jefferies has “Buy” rating and $900 target. The stock of Immunomedics, Inc. (NASDAQ:IMMU) has “Buy” rating given on Wednesday, December 6 by Cowen & Co. The firm earned “Buy” rating on Friday, May 6 by Jefferies. The firm has “Buy” rating given on Monday, October 9 by Jefferies. The stock of Immunomedics, Inc. (NASDAQ:IMMU) has “Market Perform” rating given on Tuesday, June 21 by Wells Fargo. Jefferies maintained it with “Buy” rating and $14.0 target in Tuesday, September 19 report. Jefferies maintained Immunomedics, Inc. (NASDAQ:IMMU) on Wednesday, December 6 with “Buy” rating. The stock of Immunomedics, Inc. (NASDAQ:IMMU) has “Buy” rating given on Thursday, October 6 by Jefferies. Jefferies downgraded the stock to “Hold” rating in Wednesday, July 29 report. The company was maintained on Thursday, August 17 by Jefferies.

Another recent and important Immunomedics, Inc. (NASDAQ:IMMU) news was published by which published an article titled: “Immunomedics to Present at Cowen and Company 38th Annual Health Care Conference” on March 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: